Moderna: COVID-19 vaccine nets strong antibody response for kids age 6-11
Moderna today released topline results from its ongoing phase 2/3 clinical trial of its COVID-19 vaccine for children age 6 through 11, revealing a strong antibody response against SARS-CoV-2. Moderna is evaluating the safety, tolerability, reactogenicity and effectiveness of two 50-microgram doses of its mRNA-1273 vaccine administered 28 days apart. Moderna said its data, which has not been peer-reviewed, indicates antibodies levels that were up to 1.5 times as high as those generated in adults. The majority of adverse events were deemed mild or moderate in severity, most commonly manifesting as fatigue, headache, fever and injection-site pain.
Related News Articles
Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
A CDC study released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…
Headline
Fewer than one in four health care professionals working in acute care hospitals and nursing homes were up to date with COVID-19 vaccination during the 2022-23…
Headline
Children under age 12 should receive a 0.25 milliliter dose of the 2023-24 Moderna COVID-19 vaccine, not the full vial for that age group, the Food and Drug…